The Phase 3 ADAPT OCULUS trial enrolled patients with ocular myasthenia gravis, meeting its primary endpoint with a p=0.012 improvement in MGII patient-reported ocular scores at Week 4 versus placebo, and p=0.018 on the combined PRO+PE assessment. These results support a planned supplemental biologics license application submission to FDA to expand VYVGART’s label into ocular MG.

The open-label extension of the Phase 3 ADAPT SERON trial showed rapid, sustained improvements in MG-ADL and QMG scores across MuSK-positive, LRP4-positive, and triple seronegative generalized MG patients, reinforcing VYVGART’s broad serostatus efficacy. ADAPT Jr results in adolescents (12-17 years) demonstrated minimal symptom expression in 72.7% of participants in cycle one and 80% in cycle two, with younger pediatric enrollment ongoing.

A post-hoc analysis of the ADHERE trial found that 87.5% of treatment-naïve CIDP patients receiving VYVGART Hytrulo achieved confirmed early clinical improvement with a median 39.5-day time to response. Real-world data from 225 patients indicated 85.7% of individuals switching from IVIg to VYVGART Hytrulo maintained or improved clinical stability without tolerability issues.

argenx outlined two Phase 3 CIDP studies: EMVIGORATE, comparing empasiprubart to IVIg, and EMNERGIZE, evaluating empasiprubart versus placebo. Follow-up results from a Phase 1b adimanebart study in congenital myasthenic syndromes demonstrated maintained QMG and six-minute walk test improvements through a 30-week follow-up.